Zacks Investment Research
16 Sept 2026, 15:45 UTC · 1h ago
Verdict
Headline takes no side. We score CORT +0.60 across three claims — strongly bullish.
+0.60strongly bullish
More positive than 76% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish · 0 new · 3 priced in
Corcept Therapeutics raised its full-year 2026 revenue guidance to $1.10-$1.20 billion from the previous range of $950 million to $1.05 billion.
Priced inanalysis of guidance reported earlier
So whatThe revised floor of $1.10B represents a 15.8% increase over the previous minimum guidance.
More positive than 91% of claims this week
Lifyorli generated $47.6 million in the second quarter of 2026 during its first quarter of commercial availability.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
Priced inanalysis of Q2 results reported earlier
So whatAnnualizing this first-quarter launch rate suggests an initial revenue run rate of ~$190M for the new drug.
More positive than 77% of claims this week
Korlym recorded sales of $373.5 million in the first six months of 2026, representing a 6.2% year over year increase.
Priced inanalysis of H1 results reported earlier
So whatContinued growth in the core asset supports the higher FY2026 guidance floor.
More positive than 54% of claims this week
Which stocks this story touches
More positive than 76% of ticker scores this week
The company raised its full-year revenue guidance and received FDA approval for Lifyorli, though reliance on Korlym remains a concern.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Benzinga
8h ago
+0.9%
Price agrees with the score
$111.81 vs $110.82 close before publication (Sep 15) · not market-adjusted
CORT chart →
